Prevalence and clinical correlates of bronchoreversibility in severe emphysema

European Respiratory Journal

Volumn 35, Issue 5, 2010, Pages 1048-1056

  Han, M K ^a   Wise, R ^c   Mumford, J ^e   Sciurba, F ^g   Criner, G J ^h   Curtis, J L ^a   Murray, S ^a   Sternberg, A ^c   Weinman, G ^d   Kazerooni, E ^b   Fishman, A P ⁱ   Make, B ^j   Hoffman, E A ^k   Mosenifar, Z ^f   Martinez, F J ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h TEMPLE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j DEPARTMENT OF MEDICINE   (United States)

^k UNIVERSITY OF IOWA   (United States)

more..

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease; Computed tomography; Emphysema

Indexed keywords

BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; EMPHYSEMA; FEMALE; HUMANS; LOGISTIC MODELS; MALE; NEBULIZERS AND VAPORIZERS; PHENOTYPE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77951950812     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00052509     Document Type: Article

References (43)

1. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-2073. (Pubitemid 36583301)
2. Petty T. COPD: clinical phenotypes. Pulm Pharmacol Therapeut 2002; 15: 341-351.
3. Celli B, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. (Pubitemid 38807371)
4. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555. (Pubitemid 47403272)
5. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-664. (Pubitemid 36976273)
6. Anthonisen N, Wright E. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 814-819.
7. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31: 742-750.
8. Anthonisen N, Skeans M, Wise R, et al. The effects of a smoking cessation intervention on 14.5-year mortality. A randomized clinical trial. Ann Int Med 2005; 142: 233-239.
9. Terzano C, Petroianni A, Ricci A, et al. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters. Eur Rev Med Pharmacol Sci 2005; 9: 209-215. (Pubitemid 41136436)
10. O'Donnell D, Forkert L, Webb K. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001; 18: 914-920.
11. Boschetto P, Miniati M, Miotto D, et al. Predominant emphysema phenotype in chronic obstructive pulmonary disease patients. Eur Respir J 2003; 21: 450-454. (Pubitemid 36336203)
12. Cerveri I, Pellegrino R, Dore R, et al. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 2000; 88: 1989-1995. (Pubitemid 30453902)
13. National Emphysema Treatment Trial Research Group. Rationale and design of the National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. Chest 1999; 116: 1750-1761.
14. American Thoracic Society. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
15. Hoffman E, Reinhardt J, Sonka M, et al. Characterization of the interstitial lung diseases via density-based and texture-based analysis of computed tomography images of lung structure and function. Acad Radiol 2003; 10: 1104-1118. (Pubitemid 37266302)
16. Mishima M, Oku Y, Kawakami K, et al. Quantitative assessment of the spatial distribution of low attenuation areas on X-ray CT using texture analysis in patients with chronic pulmonary emphysema. Front Med Biol Eng 1997; 8: 19-34.
17. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968. (Pubitemid 41632054)
18. National Collaborating Center for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59: Suppl. 1, 1-232.
19. Rennard S, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled b2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-1092. (Pubitemid 32378441)
20. Dahl R, Greefhorst L, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-784. (Pubitemid 32881913)
21. Mahler D, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-1091. (Pubitemid 35178706)
22. Kim WJ, Silverman EK, Hoffman E, et al. CT metrics of airway disease and emphysema in severe COPD. Chest 2009; 136: 396-404.
23. Gross NJ. Outcome measurements in COPD: are we schizophrenic? Chest 2003; 123: 1325-1327.
24. Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 1773-1777.
25. Girard WM, Light RW. Should the FVC be considered in evaluating response to bronchodilator? Chest 1983; 84: 87-89.
26. Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748. (Pubitemid 37433567)
27. Newton M, O'Donnell D, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042-1050. (Pubitemid 34280421)
28. O'Donnell D, Lam M, Webb K. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-1565. (Pubitemid 28536620)
29. O'Donnell D, Webb K, Bertley J, et al. Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. Chest 1996; 110: 18-27. (Pubitemid 26249296)
30. Martinez F, Montes de Oca M, Whyte R, et al. Lung volume reduction improves dyspnea, dynamic hyperinflation and respiratory muscle function. Am J Respir Crit Care Med 1997; 155: 1984-1990. (Pubitemid 27256129)
31. Kanner RE, Connett JE, Altose MD, et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am J Respir Crit Care Med 1994; 150: 956-961.
32. Vestbo J, Soriano JB, Anderson JA, et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir Med 2004; 98: 1045-1050. (Pubitemid 39317933)
33. Martinez FJ, Curtis JL, Sciurba F, et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med 2007; 176: 243-252. (Pubitemid 47195874)
34. Makita H, Nasuhara Y, Nagai K, et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007; 62: 932-937. (Pubitemid 350084489)
35. Anthonisen N. Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials. Am Rev Respir Dis 1989; 140: S95-S99. (Pubitemid 19231343)
36. Hansen E, Pharaneth K, Laursen L, et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1267-1271. (Pubitemid 29202565)
37. Anthonisen NR, Lindgren PG, Tashkin DP, et al. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005; 26: 45-51. (Pubitemid 40945930)
38. Dowson L, Guest P, Stockley R. Longitudinal changes in physiologic, radiological, and health status measuremetns in a1- antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001; 164: 1805-1809. (Pubitemid 33152311)
39. Campbell AH, Barter CE, O'Connell JM, et al. Factors affecting the decline of ventilatory function in chronic bronchitis. Thorax 1985; 40: 741-748.
40. Kanner R. The relationship between airways responsiveness and chronic airflow limitation. Chest 1984; 86: 54-57. (Pubitemid 14088028)
41. Rodrigues-Carballeira M, Heredia J, Rue M, et al. The bronchodilator test with increasing doses of terbutaline in chronic obstructive pulmonary disease patients. Pulm Pharmacol Therapeut 2001; 14: 61-65. (Pubitemid 32158299)
42. Mahler D, Donohue J, Barbee R, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965. (Pubitemid 29193661)
43. Miller M, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.